6.02
Schlusskurs vom Vortag:
$6.09
Offen:
$5.96
24-Stunden-Volumen:
335.03K
Relative Volume:
0.82
Marktkapitalisierung:
$1.24B
Einnahmen:
$14.78M
Nettoeinkommen (Verlust:
$-338.43M
KGV:
-1.4756
EPS:
-4.0797
Netto-Cashflow:
$-99.77M
1W Leistung:
-11.73%
1M Leistung:
+1.18%
6M Leistung:
+7.50%
1J Leistung:
+113.48%
Inventiva Adr Stock (IVA) Company Profile
Compare IVA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
IVA
Inventiva Adr
|
6.02 | 1.26B | 14.78M | -338.43M | -99.77M | -4.0797 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-21 | Eingeleitet | TD Cowen | Buy |
| 2024-11-12 | Eingeleitet | UBS | Neutral |
| 2023-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-19 | Hochstufung | Societe Generale | Sell → Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2022-11-15 | Herabstufung | Societe Generale | Buy → Sell |
| 2021-03-08 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Eingeleitet | ROTH Capital | Buy |
| 2020-08-04 | Eingeleitet | Guggenheim | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Inventiva Adr Aktie (IVA) Neueste Nachrichten
Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect? - Finviz
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Inventiva reports preliminary 2025¹ fiscal year financial results - GlobeNewswire Inc.
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Increase in Short Interest - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update - MarketBeat
Are You Looking for a Top Momentum Pick? Why Inventiva S.A. Sponsored ADR (IVA) is a Great Choice - Yahoo Finance
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Inventiva (NASDAQ:IVA) Shares Gap Up on Analyst Upgrade - Defense World
Inventiva’s (IVA) “Buy” Rating Reiterated at UBS Group - Defense World
Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know - primepublishers.com
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Inventiva (NASDAQ:IVA) Sees Strong Trading VolumeHere's Why - MarketBeat
The time has not yet come to remove your chips from the table: Inventiva ADR (IVA) - setenews.com
Debt to assets ratio of Inventiva SA ADR – LSX:A2P796 - TradingView — Track All Markets
Net margin % of Inventiva SA ADR – LSX:A2P796 - TradingView
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Weekly Investment Analysts’ Ratings Changes for Inventiva (IVA) - Defense World
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Inventiva (NASDAQ:IVA) Price Target Cut to $11.00 by Analysts at Guggenheim - Defense World
ETFs Investing in Inventiva SA ADR Stocks - TradingView
Form 424B5 Inventiva S.A. - StreetInsider
Its Stock Has Paid Off Big Time For Inventiva ADR - Setenews
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Inventiva (NASDAQ:IVA) Upgraded at Wolfe Research - Defense World
Assemblée Générale Mixte du 27 novembre 2025 - GlobeNewswire Inc.
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Up 461.9% in October - MarketBeat
How Does Wall Street Rate Shares Of Inventiva ADR (IVA)? - fostersleader.com
Inventiva (NASDAQ:IVA) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Inventiva (NASDAQ:IVA) Raised to “Hold” at Wall Street Zen - Defense World
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Inventiva Stock Falls 9% Following Announcement of a Dilutive Financing Program - Idéal Investisseur
FY2025 EPS Estimates for Inventiva Cut by HC Wainwright - MarketBeat
Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva Stock Price, Quotes and Forecasts | NASDAQ:IVA - Benzinga
Inventiva (NASDAQ:IVA) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Inventiva SA Reports Progress and Challenges in 2025 - The Globe and Mail
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Finanzdaten der Inventiva Adr-Aktie (IVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):